In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Vivoryon Therapeutics AG

https://www.vivoryon.com/

Latest From Vivoryon Therapeutics AG

Vivoryon Brings 'Diversity' To Therapeutic Approach In Alzheimer’s

Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.

Innovation Clinical Trials

Interview: Vivoryon Raises €43m After Alzheimer's Revival

New life has been breathed into Alzheimer's research following the reversal of fortunes for Biogen's aducanumab and Vivoryon is benefiting from the upturn in sentiment for the field.

Financing Companies

Vivoryon And MorphoSys Link To Accelerate Novel Small Molecule Checkpoint Silencing Approach

Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.

ImmunoOncology Deals

Probiodrug CEO Outlines Phase IIb Plans For Potential Alzheimer’s Treatments

Probiodrug is ramping up plans to run Phase IIb Alzheimer's disease trials on the back of biomarker data that indicates that its approach to targeting pyroglutamate-Abeta is a promising therapeutic strategy. CEO Konrad Glund spoke to Scrip at the 2018 Biotech Showcase.

Business Strategies Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Probiodrug AG
UsernamePublicRestriction

Register